---
document_datetime: 2024-07-26 13:18:34
document_pages: 22
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/atriance-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: atriance-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 11.1346581
conversion_datetime: 2025-12-28 11:34:45.237171
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Atriance

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| N/0067               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 25/07/2024                          |                                             | PL                               |                                   |
| PSUSA/2132/ 202310   | Periodic Safety Update EU Single assessment - nelarabine                                         | 13/06/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IAIN/0066/G   | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   | 30/04/2024   |            | Annex II and PL        |                                                                                                                                                                                                                                                                   |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0064        | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                          | 07/12/2023   |            | PL                     |                                                                                                                                                                                                                                                                   |
| S/0062        | 16th annual re-assessment                                                                                                                                                                                                                                                                                                                                 | 09/11/2023   | n/a        |                        | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Atriance should be maintained. |
| IA/0063       | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                             | 12/09/2023   | n/a        |                        |                                                                                                                                                                                                                                                                   |
| N/0061        | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                          | 16/01/2023   |            | PL                     |                                                                                                                                                                                                                                                                   |
| T/0060        | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                       | 16/11/2022   | 09/12/2022 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                   |
| S/0058        | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                     | 10/11/2022   | n/a        |                        |                                                                                                                                                                                                                                                                   |
| IA/0059       | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process                                                                                                                                                                                                                                                    | 22/09/2022   | n/a        |                        |                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                    | of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |            |                 |                                                                                                                                                                                                                                                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/1521            | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 23/06/2022 | n/a        |                 |                                                                                                                                                                                                                                                                   |
| S/0055             | 14th annual re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 11/11/2021 | n/a        |                 | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Atriance should be maintained. |
| IAIN/0056/G        | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites | 24/09/2021 | 12/11/2021 | Annex II and PL |                                                                                                                                                                                                                                                                   |
| PSUSA/2132/ 202010 | Periodic Safety Update EU Single assessment - nelarabine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 10/06/2021 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| S/0051      | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 12/11/2020   | n/a        |                                  |           |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------|
| IB/0053     | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 30/10/2020   | 12/11/2021 | SmPC, Annex II, Labelling and PL |           |
| IA/0052/G   | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test | 26/08/2020   | n/a        |                                  | procedure |
| IAIN/0050/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging                                                                                                                                                                                                                                                                                                   | 25/02/2020   | n/a        |                                  | site      |

<div style=\"page-break-after: always\"></div>

| IAIN/0049/G   | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP -   | 25/02/2020   | 27/08/2020   | Annex II and PL       |                                                                                                                  |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------------|------------------------------------------------------------------------------------------------------------------|
| S/0048        | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 17/10/2019   | n/a          |                       |                                                                                                                  |
| II/0046/G     | This was an application for a group of variations. Update of Annex II to remove the existing specific obligation Study NLR506AUS02T 'Intensified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 17/10/2019   | 27/08/2020   | SmPC, Annex II and PL | Men with partners who are pregnant or could become pregnant should use condoms during treatment with nelarabine. |

<div style=\"page-break-after: always\"></div>

|           | methotrexate, nelarabine and augmented BFM therapy for children and young adults with newly diagnosed T-ALL and T-LBL'; a new SOB is introduced in Annex II to provide yearly updates on any new information concerning the efficacy and safety of the product in the approved indication. Additionally, section 4.6 of the SmPC is updated in order to revise information on the male and female contraception taking into consideration available non-clinical and clinical safety data as well as internal MAH's guidelines based on information from literature, health authority and working group guidelines. Minor corrections are also made to sections 4.8 and 5.3 of the SmPC. Moreover, the MAH took the opportunity to update details of the local representatives in the PL and introduce minor editorial changes in the PI. The revised RMP version 10.1 has been agreed. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH   |            |            |                           |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------|
| II/0047/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 19/09/2019 | 27/08/2020 | SmPC, Annex II, Labelling |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| manufacturing site for site B.II.b.1.b - Replacement manufacturing site for site B.II.b.1.f - Replacement manufacturing site for manufacturing process manufacturing operation(s) release, batch control, sterile medicinal products aseptically manufactured) immunological medicinal B.II.b.2.a - Change to arrangements and quality Replacement/addition control/testing takes place B.II.b.2.a - Change to arrangements and quality Replacement/addition control/testing takes place B.II.b.2.c.2 - Change to arrangements and quality Including batch control/testing B.II.b.3.a - Change in the finished or intermediate in the manufacturing process B.II.b.3.a - Change in the finished or intermediate in the manufacturing process B.II.b.3.a - Change in   | and PL   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.d - Change in the manufacturing process of the finished or intermediate product - Introduction of a non-standard terminal sterilisation method B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of   |            |     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0045/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 31/01/2019 | n/a |

<div style=\"page-break-after: always\"></div>

| manufacturing sites A.7 - Administrative change manufacturing sites B.I.a.1.f - Change in the starting material/reagent/intermediate Changes to quality control the AS -replacement or batch control/testing takes B.I.a.1.f - Change in the starting material/reagent/intermediate Changes to quality control the AS -replacement or batch control/testing takes B.I.a.1.f - Change in the starting material/reagent/intermediate Changes to quality control the AS -replacement or batch control/testing takes B.I.a.1.g - Change in the starting material/reagent/intermediate Introduction of a new manufacturer not supported by an ASMF update to the relevant B.I.a.1.z - Change in the starting material/reagent/intermediate variation B.I.a.1.z - Change in the starting material/reagent/intermediate variation B.I.a.2.a - Changes in the AS - Minor change   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor   |            |     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| S/0044    | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 15/11/2018 | n/a |
| IA/0043/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 31/07/2018 | n/a |

<div style=\"page-break-after: always\"></div>

|                    | B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier   |            |            |                                  |                                                                                                                                                                                                                                                                        |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0950            | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                             | 18/06/2018 | n/a        |                                  |                                                                                                                                                                                                                                                                        |
| PSUSA/2132/ 201710 | Periodic Safety Update EU Single assessment - nelarabine                                                                                                                                                                                                                                     | 14/06/2018 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| T/0041             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                          | 26/03/2018 | 30/04/2018 | SmPC, Labelling and PL           |                                                                                                                                                                                                                                                                        |
| IB/0039            | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                | 05/01/2018 | 30/04/2018 | Annex II                         |                                                                                                                                                                                                                                                                        |
| S/0038             | Annual re-assessment.                                                                                                                                                                                                                                                                        | 09/11/2017 | n/a        |                                  |                                                                                                                                                                                                                                                                        |
| R/0037             | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                      | 21/04/2017 | 16/06/2017 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Atriance in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| S/0034             | Annual re-assessment.                                                                                                                                                                                                                                                                        | 10/11/2016 | n/a        |                                  |                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| IB/0036     | - Change in the specification parameters limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 09/11/2016   | n/a        |    | B.I.b.1.z and/or   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----|--------------------|
| IA/0035     | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 15/09/2016   | n/a        |    |                    |
| N/0033      | Update of the package leaflet with revised contact details of the local representatives for France and Spain. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                              | 26/07/2016   | 16/06/2017 | PL |                    |
| IAIN/0032/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a | 11/05/2016   | n/a        |    |                    |

<div style=\"page-break-after: always\"></div>

| manufacturing site for the site B.II.b.1.a - Replacement manufacturing site for the site B.II.b.1.a - Replacement manufacturing site for the site B.II.b.1.a - Replacement manufacturing site for the site B.II.b.1.a - Replacement manufacturing site for the site B.II.b.1.a - Replacement manufacturing site for the site B.II.b.1.a - Replacement manufacturing site for the site B.II.b.1.a - Replacement manufacturing site for the site B.II.b.1.a - Replacement manufacturing site for the site B.II.b.1.a - Replacement manufacturing site for the site B.II.b.1.a - Replacement manufacturing site for the   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                    | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                            |            |            |                 |                                                                                                                                                                                                                                                                   |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0031             | 8th Annual Re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 19/11/2015 | 12/01/2016 | Annex II        | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that Marketing Authorisation of Atriance should be maintained. |
| IB/0030            | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                              | 02/09/2015 | n/a        |                 |                                                                                                                                                                                                                                                                   |
| IAIN/0029/G        | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 13/07/2015 | 12/01/2016 | Annex II and PL |                                                                                                                                                                                                                                                                   |
| PSUSA/2132/ 201410 | Periodic Safety Update EU Single assessment - nelarabine                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 11/06/2015 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| II/0027   | Submission of data from a Post-Marketing Surveillance Study for Atriance in the indicated patient population under 21 years of age receiving 650 mg/m2 dose of nelarabine. This variation intends to fulfil ANX II Specific Obligation SOB 004.2 and Article 46 of the Paediatric legislation. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH is required   | 21/05/2015   | 12/01/2016   | Annex II               | where significant assessment   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|--------------------------------|
| T/0028    | Transfer of Marketing Authorisation from Glaxo Group Ltd. to Novartis Europharm Limited. Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                       | 30/03/2015   | 24/04/2015   | SmPC, Labelling and PL |                                |
| II/0024/G | This was an application for a group of variations. Approved scope: B.II.e.1.a - 3 Change in quantitative composition of sterile medicinal product: to register Datwyler FM457/0 Omniflex 3G bromobutyl rubber stopper. B.II.e.7.b - Replacement of a supplier of packaging components: to register Datwyler at Industrieterrein Kolmen 1519, BE-3570, Aiken, Belgium as a rubber                                                                                                                                                                                   | 20/11/2014   | n/a          |                        | stoppers supplier.             |

<div style=\"page-break-after: always\"></div>

|         | Refused scope: B.II.f.1.d - Change in storage conditions of the finished product: to register storage conditions of 'store below 25 C'. B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product   |            |            |          |                                                                                                                                                                                                                                                                   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0025  | 7th Annual Re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 23/10/2014 | n/a        |          | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that Marketing Authorisation of Atriance should be maintained. |
| IB/0023 | To extend the due date for an annex II condition from Oct. 2014 to January 2015. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                              | 10/09/2014 | 24/04/2015 | Annex II |                                                                                                                                                                                                                                                                   |
| IA/0022 | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 17/01/2014 | n/a        |          |                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | product formulation - Change that does not affect the product information                                                                                         |            |            |                            |                                                                                                                                                                                                                                                               |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0021    | 6th Annual Re-assessment                                                                                                                                          | 24/10/2013 | 20/12/2013 | Annex II                   |                                                                                                                                                                                                                                                               |
| N/0019    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                  | 17/09/2013 | 20/12/2013 | Labelling                  |                                                                                                                                                                                                                                                               |
| IAIN/0020 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                    | 01/07/2013 | 20/12/2013 | SmPC and PL                |                                                                                                                                                                                                                                                               |
| IG/0279   | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                        | 18/04/2013 | 20/12/2013 | SmPC, Labelling and PL     |                                                                                                                                                                                                                                                               |
| IG/0275   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                    | 15/03/2013 | n/a        |                            |                                                                                                                                                                                                                                                               |
| S/0016    | '5th Annual Re-assessment'                                                                                                                                        | 20/09/2012 | n/a        |                            | The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the MAH and having re-assessed the benefit/risk profile of the medicinal product, concluded that the benefit/risk balance for the product remains favourable. |
| R/0013    | Renewal of the marketing authorisation.                                                                                                                           | 19/04/2012 | 18/06/2012 | Annex II, Labelling and PL |                                                                                                                                                                                                                                                               |
| IB/0014   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time | 11/05/2012 | n/a        |                            |                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|           | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0150/G | This was an application for a group of variations. C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system                                                                                                                                                                                                                                               | 05/04/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0012   | Update of section 4.8 of the SmPC in order to add rhabdomyolysis and blood creatine phosphokinase increased as rare adverse reactions. The package leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to make minor editorial changes. Furthermore, the MAH proposed to bring the product information in line with the latest QRD template (version 8, revision 1). C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 16/02/2012 | 21/03/2012 | SmPC, Annex II, Labelling and PL | A cumulative review cases of rhabdomyolysis and/or creatine phosphokinase (CPK) increased was conducted and retrieved 16 cases, as of 16 August 2011. Although most of the 16 cases were confounded due to concurrent disease(s) and/or concomitant medications, there were five reports which suggest a potential causal relationship to nelarabine was considered possible. As a consequence, rhabdomyolysis and elevated creatine phosphokinases in the blood were added to the product information as adverse reactions with a rare frequency. |
| S/0010    | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 22/09/2011 | 24/11/2011 | Annex II                         | 4th Annual Re-assessment The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the MAH and having re-assessed the benefit/risk profile of the medicinal product, concluded that the benefit/risk balance for the                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |     |          | product remains favourable.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|-------------------------------|
| IB/0009/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                 | 18/05/2011 | n/a |          |                               |
| IB/0008/G | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling | 18/05/2011 | n/a |          |                               |
| IG/0034/G | This was an application for a group of variations. C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the contact details of the QPPV                                                                                                                                                                                                                                                                                                                                                                                                                          | 06/01/2011 | n/a | Annex II |                               |

<div style=\"page-break-after: always\"></div>

|        | C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of   |            |            |                                  |                                                                                                                                                                                                                                                                                        |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0007 | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 23/09/2010 | 29/11/2010 | SmPC, Annex II, Labelling and PL | 3rd Annual Re-assessment The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the MAH and having re-assessed the benefit/risk profile of the medicinal product, concluded that the benefit/risk balance for the product remains favourable. |

<div style=\"page-break-after: always\"></div>

| II/0006   | Update of the Detailed Description of the Pharmacovigilance System (DDPS) including change of the Qualified Person for Pharmacovigilance (QPPV). Consequently, Annex II has been updated with the new version number. Changes to QPPV Update of DDPS (Pharmacovigilance)   | 17/12/2009   | 20/01/2010   | Annex II                         | The DDPS has been updated (version 7.2) to reflect the change of the QPPV as well as to notify other changes to the DDPS performed since the last approved version. Consequently, Annex II has been updated using the standard text including the new version number of the agreed DDPS. The CHMP considers that the Pharmacovigilance System as described by the MAH fulfils the requirements.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0005   | IB_17_a_Change in re-test period of the active substance                                                                                                                                                                                                                   | 14/10/2009   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                   |
| S/0004    | Annual re-assessment.                                                                                                                                                                                                                                                      | 24/09/2009   | 24/09/2009   |                                  | 2nd Annual Re-assessment The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the Marketing Authorisation Holder and having re-assessed the benefit/risk profile of Atriance, recommended no amendments to Annexes of the Commission Decision, and that the marketing authorisation remains under exceptional circumstances.                           |
| II/0003   | Changes to QPPV Update of DDPS (Pharmacovigilance)                                                                                                                                                                                                                         | 19/02/2009   | 18/03/2009   | Annex II                         | The DDPS has been updated (version 6.2) to reflect the change of the Qualified Person for Pharmacovigilance (QPPV) as well as to notify other changes to the DDPS performed since the last approved version. Consequently, Annex II has been updated using the standard text including the new version number of the agreed DDPS.                                                                 |
| S/0001    | Annual re-assessment.                                                                                                                                                                                                                                                      | 25/09/2008   | 19/11/2008   | SmPC, Annex II, Labelling and PL | 1st Annual Reassessment The CHMP, having reviewed the evidence of compliance with the specific obligations submitted by the Marketing Authorisation Holder and having re-assessed the benefit/risk profile of Atriance, recommended the                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|         |                                                                            |            |     |      | amendments of Annexes I, II and III of the Commission Decision, and that the marketing authorisation remains under exceptional circumstances.   |
|---------|----------------------------------------------------------------------------|------------|-----|------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0002 | IB_42_a_01_Change in shelf-life of finished product - as packaged for sale | 05/08/2008 | n/a | SmPC |                                                                                                                                                 |